EUCTR2008-002120-29-GB进行中（未招募）不适用
A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Odanacatib) in Prolonging Bone Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer - MK-0822 (Odanacatib) in Men with Hormone-Refractory Prostate Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Patient is a man =18 years of age on the day of signing the informed consent.
- •Patient has hormone-refractory (androgen-independent) prostate cancer, defined as 3 rising, consecutive, historical PSA values following bilateral orchiectomy, or while receiving continuous (not intermittent) androgen-deprivation therapy. The second and third historical PSA tests (i.e., values obtained prior to the screening visit) must be separated from the previous test by at least 2 weeks, and the second and third values must each be = 1.0 ng/mL.
- •Patient has a serum testosterone <50 ng/dL at screening.
- •Patient is at increased risk for prostate cancer progression defined as either an elevated PSA of =8 ng/mL obtained at the screening visit as measured by the central laboratory, or a PSA doubling time (PSADT) of =10 months (defined as = 300 days).
- •Patient underwent bilateral orchiectomy 3 months or more (i.e., =90 days) prior to Visit 1, or is receiving androgen-deprivation therapy (ADT) and is on a stable GnRH agonist regimen for at least 3 months (i.e., =90 days) prior to Visit 1. ADT cannot be modified between Visit 1 and Visit 2 (the randomization visit). Androgen-deprivation therapy may include gonadotropin-releasing hormone agonists (GnRH) such as leuprolide, goserelin, or triptorelin. Patients receiving anti-androgen (e.g., flutamide, bicalutamide, nilutamide) monotherapy are not eligible, however, patients receiving an anti-androgen in combination with androgen deprivation (with a GnRH agonist or bilateral orchiectomy) are eligible, and in this case these therapies cannot be modified between Visit 1 and Visit 2. Patients who have failed anti-androgen monotherapy in the past, and are now failing androgen deprivation (with a GnRH agonist or bilateral orchiectomy) are also eligible.
- •Patient has not undergone radiotherapy, OR if patient has undergone radiotherapy he has recovered and is at least 4 weeks from the previous radiotherapy at the time of screening (Visit 1).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient has bone metastases, or has a history of bone metastases: patient must have a negative bone scan obtained during the screening period, or within 1 month prior to the screening visit (Visit 1). All bone scans and associated imaging studies used for eligibility purposes must be adjudicated by the central radiologist before the patient may be randomized at Visit 2.
- •Patient has other distant metastases (e.g., visceral, including brain, or soft-tissue). Patients with regional lymph nodal metastases are eligible.
- •Patient has ANY of the following:
- •a) is currently receiving a bisphosphonate (e.g., etidronate, clodronate, tiludronate, pamidronate, alendronate, ibandronate, risedronate, olpadronate, neridronate, zoledronate), or other drug therapy for osteoporosis;
- •b) has been treated with an oral bisphosphonate within the 6 months prior to Visit 1;
- •c) has been treated with an intravenous bisphosphonate within the 12 months prior to Visit 1.
- •Patient has received chemotherapy within the 2 years prior to Visit 1 (for example, doxorubicin, cyclophosphamide, estramustine, paclitaxel, docetaxel, etoposide, vinblastine, 5-fluorouracil, interferon, mitoxantrone). Patients may not start chemotherapy between Visit 1 and Visit 2. This exclusion criterion does not include androgen-deprivation therapy, which is permitted and expected in patients entering this study (e.g., gonadotropin-releasing hormone agonists such as leuprolide, goserelin, or triptorelin).
- •Patient is using any of the following potent inhibitors of CYP3A4 within 2 weeks prior to starting blinded study medication: (a) systemically administered azole antifungals such as ketoconazole, fluconazole, itraconazole, miconazole, posaconozole, ravuconazole, and voriconazole; (b) nefazodone; (c) the macrolide antibiotics clarithromycin, dirithromycin, erythromycin, and troleandomycin, however, azithromycin, is permitted. The use of any other macrolide antibiotic requires approval by the SPONSOR’s clinical representative. Patients who discontinue these medications at least two weeks prior to starting blinded study medication are eligible.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2020-002251-38-DEVertex Pharmaceuticals Incorporated70
招募中
不适用
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in Non Small Cell Lung Cancer PatientsDiseases of th respiratory systemKCT0000434Hanmi Pharm30
进行中（未招募）
1 期
A study to evaluate CM24 in combination with nivolumab in adults with solid tumoursEUCTR2020-005016-21-ESFamewave Ltd.74
进行中（未招募）
不适用
A study in people with Cystic Fibrosis (a rare hereditary pulmonary disease) to assess the long-term efficacy and safety of a combination of two experimental drugsCystic fibrosis in patients homozygous or heterozygous for the F508del-CFTR MutationMedDRA version: 18.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-000604-41-IEVertex Pharmaceuticals Incorporated1,000
已完成
3 期
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutatio10083624Cystic FibrosisNL-OMON41659Vertex Pharmaceuticals28